Enhanced expression of tissue factor (TF) is associated with the occurrence of coronary disease, strokes and arterial thrombosis. We demonstrated previously that adenosine inhibits TF expression in human umbilical vein endothelial cells (HUVECs) stimulated with inflammatory mediators. In the present study, we evaluated the mechanism of adenosine-induced inhibition of TF expression in HUVECs. The adenosine inhibitory activity on thrombin-induced TF expression in HUVECs was potentiated by the NO precursor, L-arginine, but it was significantly suppressed by the NO scavenger, 2(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide, and by endothelial NO synthase inhibitors, N G -monomethyl-L-arginine and N G -nitro-L-arginine methyl ester, in a dose-dependent manner. The concentrations of nitrites, cGMP and cAMP in the culture medium of HUVECs treated with a mixture of thrombin and adenosine were significantly higher compared with the culture medium of HUVECs treated with thrombin alone. Northern blotting showed that thrombin decreases and adenosine increases the eNOS mRNA expression in HUVECs. A cAMP-dependent protein kinase inhibitor suppressed NOmediated TF inhibition in a dose-dependent manner. Overall, these results suggest that adenosine inhibits thrombin-induced TF expression in endothelial cells by a NO-mediated mechanism, and that increased intracellular formation of cAMP is implicated in this inhibitory activity of NO.
INTRODUCTION
Tissue factor (TF) is a transmembrane receptor, which after binding to activated Factor VII (Factor VIIa) initiates the activation of the extrinsic pathway of blood coagulation [1] . Under normal physiological conditions, TF is not expressed in vascular endothelial cells and monocytes, but it can be induced by inflammatory stimulants such as lipopolysaccharide, thrombin, oxi- [7, 8] that the adenosine potentiator, dilazep, and adenosine itself can also down-regulate the expression of TF induced by TNF-α or thrombin on endothelial cells ; this mechanism of adenosine-induced down-regulation of TF remains to be clarified.
Adenosine is a naturally occurring purine nucleoside that may be intracellularly produced by the hydrolysis of AMP or by the catabolism of S-adenosylhomocysteine [9] . Under conditions of hypoxia or cellular activation the intracellular pool of adenosine increases, and it may be released from the cell or tissue affected [9] . In the cardiovascular system, adenosine is known to protect vascular endothelial cells against ischaemia-reperfusion injury, oxidative stress and to play an important role in the maintenance of vascular wall tone [9] . In addition to adenosine, NO has been also shown to exert cytoprotective activity against vascular endothelial injury [10] . NO is a free gas generated via the oxidation of a terminal guanidinium nitrogen on the amino acid L-arginine through a reaction catalysed by NO synthase (NOS), yielding the co-product L-citrulline in addition to NO [11] . Inhibition of platelet activation and TF expression on monocytes are some of the cytoprotective activities of NO [12] [13] [14] . In the present study, we evaluated whether the inhibitory activity of adenosine on thrombin-induced TF activity in endothelial cells is mediated by NO.
METHODS

Materials
Human Factor VIIa and Factor X were kindly provided by Dr Tomohiro Nakagaki (Chemo-Sera Therapeutic Institute, Kumammoto, Japan). Human thrombin was purchased from Yoshitomi Pharmaceuticals (Osaka, Japan). The synthetic peptide substrate for Factor Xa,
N-benzoyl-L-isoleucyl-L-glutamyl-glycyl-L-arginine-p-
nitroanilide hydrochloride (S2222), was purchased from Chromogenic (Mo$ lndal, Sweden). Hydrocortisone and the inhibitors of NOS, N G -nitro-L-arginine methyl ester (L-NAME) and N G -monomethyl-L-arginine (L-NMMA), were purchased from Wako Chemicals (Osaka, Japan). The NO scavenger 2(4-carboxyphenyl)-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxide (carboxy-PTIO) was purchased from Funakoshi (Tokyo, Japan) and L-arginine from Nacalai Tesque (Kyoto, Japan). Dulbecco's phosphate-buffered saline, BSA and adenosine were from Sigma (St. Louis, MO, U.S.A.). Glyceraldehyde-3-phosphate dehydrogenase and endothelial NOS (eNOS) DNA probes were from Cayman (Ann Arbor, MI, U.S.A.), and 8-( p-sulphophenyl)-theophylline (8-SPT) from Research Biochemicals International (Natick, MA, U.S.A.). The reagents used to check the viability of the cells, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazoliumsodium and 1-methoxy-5-methyl-phenazinium methylsulphate, were purchased from Dojindo (Kumamoto, Japan). Epithelial cell and fibroblast growth factors were purchased from Boehringer Mannheim (Mannheim, Germany) and [α-$#P]dCTP from Daiichi Kagahu (Tokyo, Japan). The NO donor FK409 was a kind gift from Fujisawa (Osaka, Japan). The inhibitor of the cAMP-dependent protein kinase inhibitor Rp-adenosine-3h,5h-cyclic monophosphorothioate (Rp-cAMPS), and the inhibitor of the phosphodiesterase II, erythro-9-(2-hydroxy-3-nonyl)adenine:HCL (EHNA), were purchased from Biomol (Plymouth Meeting, PA, U.S.A.).
Cell culture
Human umbilical vein endothelial cells (HUVECs) were purchased from Sanko Junyaku (Tokyo, Japan). The cells were cultured in MCDB 131 medium (Chlorella Industry, Tokyo, Japan) supplemented with 5 % heatinactivated fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY, U.S.A.), 50 µg\ml gentamycin (Nacalai Tesque), 50 ng\ml amphotericin B (Bristol-Myers Squibb, New Brunswick, NJ, U.S.A.), 50 µg\ml ascorbic acid, 0.5 µg\ml hydrocortisone, 10 µg\ml vascular endothelial cell growth factor (Beckon Dickinson, Bedford, MA, U.S.A.), 8 ng\ml fibroblast growth factor and 20 ng\ml epithelial cell growth factor at 37 mC under an atmosphere of 95 % air and 5 % CO # . The viability of the cells in different experiments was evaluated using a cell counting kit.
Determination of cell surface TF activity
TF activity was determined by the degree of Factor X activation by the Factor VIIa-TF complex on HUVECs after stimulation with thrombin. The cells (48-well plate, 5i10& cells\well) were incubated for 5 h in the presence of various concentrations of thrombin diluted in MCDB 131 medium without FBS and supplements, and then the cells were washed twice with Hepes-buffered saline (20 mM Hepes and 150 mM NaCl, pH 7.5) containing 5 mM CaCl # . Thereafter, the cells were incubated in the presence of a mixture of 50 µl of 4 nM Factor VIIa, 50 µl of 1 µM Factor X and 150 µl of Hepes-buffered saline, containing 5 mM CaCl # , for 60 min at 25 mC. The reaction was stopped by adding 10 µl of 100 mM EDTA, and generated Factor Xa was determined using 100 µM S2222. The reaction was stopped by the addition of 10 µl of 20% acetic acid, and colour development was determined by measuring the absorbance at 405 nm with a EAR 340 microplate reader (SLT-Lab, Salzburg, Austria).
Assessment of production of NO, cGMP and cAMP induced by adenosine in HUVECs
NO is an unstable free radical that rapidly converts to nitrite and nitrate in the presence of oxygen [14] . To evaluate whether adenosine induces the increased formation of NO in HUVECs, these cells were incubated overnight in FBS-and supplement-free MCDB 131 medium, at 37 mC under an atmosphere of 95 % air and 5% CO # , in the presence of various concentrations of the nucleoside. In similar assays, HUVECs were also stimulated with 10 µM adenosine in the presence of 1 mM 8-SPT or 2 mM NOS inhibitors, L-NMMA or L-NAME. The total concentration of nitrite and\or nitrate in the medium was measured by a modified Griess reaction by using a commercial colourimetric assay kit (Cayman) according to the manufacturer's instructions [15] . The sensitivity of the assay was 2 µM nitrite\nitrate, and the inter-assay and intra-assay coefficients of variation were less than 10 %. For all experiments, background levels of nitrite\nitrate in the culture medium were determined by a parallel incubation of medium containing the appropriate reagents in the absence of HUVECs. The production of NO by HUVECs was determined by subtracting the background levels of nitrite\nitrate obtained in the absence of HUVECs from values obtained in the presence of the cells. Interaction of NO with the haem component of soluble guanylate cyclase stimulates enzymic conversion of GTP into cGMP ; thus, as a marker of NO generation, the intracellular levels of cGMP were also determined in adenosine-treated HUVECs. The total content of cGMP or cAMP in adenosine-treated HUVECs was measured using a commercial cGMP or cAMP enzyme immunoassay kit from Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, U.K.). The intra-assay and inter-assay coefficients of variation of the cGMP and cAMP assays were 7 % and 10 % respectively.
Assessment of the effect of NO scavenger, NO inhibitors and L-arginine on adenosineinduced inhibition of cell surface TF activity
HUVECs were cultured in 48-well microplates to confluency, and then stimulated with 500 nM thrombin and 10 µM adenosine in the presence of various concentrations of carboxy-PTIO, L-NMMA, L-NAME or L-arginine. After 5 h, the cells were washed, and the effect of TF activity on HUVECs was determined as described above.
Evaluation of adenosine effect on eNOS or inducible NOS (iNOS) gene expression in HUVECs by Northern-blot analysis
For total RNA preparation, confluent HUVEC monolayers in 100-mm dishes were incubated overnight in FBS-and supplement-free MCBD 131 medium containing no stimulant, 500 nM thrombin alone, 10 µM adenosine alone, a mixture of 500 nM thrombin and 10 µM adenosine, or a mixture of 500 nM thrombin, 10 µM adenosine and 1 mM 8-SPT. Total RNA was extracted from cells by the guanidine-isothiocyanate procedure using Trizol Reagent. Total RNA (15 µg) were run in a 2 % agarose gel containing 660 mM de-ionized formaldehyde, transferred for 24 h by capillary action on to a nylon membrane and then dried for 2 h under vacuum at 80 mC. The membrane was pre-hybridized in a solution containing 20 mM Tris\HCl, pH 7.5, 750 mM NaCl, 2.5 mM EDTA, 1 % SDS, 0.5 % Denhardt's solution and 50 % de-ionized formamide, and then hybridized with eNOS, iNOS or GADPH cDNA probes labelled with [α-$#P]dCTP. The membrane was then washed twice in 0.2iSSC (0.15 M NaCl\0.015 M sodium citrate) and 0.1 % SDS at 60 mC for 30 min, exposed to imaging plates and analysed using BAS-2000 Image Analyzer. The amount of eNOS or iNOS mRNA was normalized against the glyceraldehyde-3-phosphate dehydrogenase mRNA.
Evaluation of the effect of cAMP-dependent protein kinase inhibitor on NO-mediated inhibition of TF activity on HUVECs
To evaluate the role of cAMP-dependent protein kinase in the inhibitory activity of NO on thrombin-induced TF activity, HUVECs cultured in 48-well plates were incubated overnight in the presence of 250 nM thrombin, 25 µM FK409, a NO donor, and increasing concentrations of Rp-cAMPS, a cAMP-dependent protein kinase inhibitor. The cells were then washed, and the effect of TF activity on HUVECs was determined as described above.
Evaluation of the effect of phosphodiesterase II inhibitor on TF activity on HUVECs
Intracellular cGMP is known to inhibit the activity of phosphodiesterase II leading to increased intracellular formation of cAMP. To evaluate the role of phosphodiesterase II on TF activity on HUVECs induced by thrombin, HUVECs cultured in 48-well plates were incubated overnight in the presence of 250 nM thrombin, a mixture of 250 nM thrombin and 10 µM adenosine, or a mixture of 250 nM thrombin and 10 µM adenosine plus increasing concentrations of EHNA, an inhibitor of phosphodiesterase II. The cells were then washed, and the effect of TF activity on HUVECs was determined as described above.
Measurement of adenosine secretion induced by NO donor from HUVECs
To evaluate whether NO itself stimulates the secretion of adenosine in HUVECs, these cells were cultured in FBSfree medium in the presence or absence of the NO donor, FK409, at 37 mC for 24 h under an atmosphere of 95 % air and 5 % CO # . Adenosine concentration in the conditioned medium was then measured using a commercial radio-immunoassay kit from Yamasa (Chiba, Japan).
Statistical analysis
Results are expressed as the meanpS.E.M., unless otherwise specified. The difference between the means of two variables was calculated by the Mann-Whitney U-test, and between three or more variables by analysis of variance. A P 0.05 was considered as statistically significant. Statistical analyses were carried out using the StatView 4.5 package for the Macintosh (Abacus Concepts, Berkeley, CA, U.S.A.).
RESULTS
Effect of adenosine, 8-SPT and NOS inhibitors on NO, cGMP and cAMP production
To determine the effect of adenosine on NO production by HUVECs, we measured the levels of nitrite\nitrate and cGMP in conditioned media and homogenates from HUVECs treated with adenosine. High levels of nitrite\ (A) HUVECs were stimulated with 500 nM thrombin and 10 µM adenosine in the presence of various concentrations of carboxy-PTIO. NO scavenger blocked the inhibitory activity of adenosine on TF expression. TF activity is expressed as a percentage of the control activity (thrombin alone). *P 0.05 compared with thrombin alone, and **P 0.05 compared with 500 nM thrombinj10 µM adenosine without NO scavenger. (B) HUVECs were stimulated with 500 nM thrombin and 10 µM adenosine in the presence of various concentrations of the NOS inhibitor L-NMMA (closed columns) or L-NAME (open columns). NOS inhibitors blocked the inhibitory activity of adenosine on TF expression. TF activity is expressed as a percentage of the control activity (thrombin alone). Results are expressed as the meanpS.E.M. for four independent experiments, each done in quadruplicate. *P 0.05 compared with thrombin alone, and **P 0.05 compared with 500 nM thrombinj10 µM adenosine without NO scavenger.
nitrate ( Figure 1A) were observed in the conditioned medium and homogenates from HUVECs cultured in the presence of adenosine ; this stimulatory activity of adenosine was inhibited by 8-SPT, L-NMMA and L-NAME, suggesting the important role of adenosine in NO formation. The levels of cGMP, which increased in the presence of adenosine, were also decreased by 8-SPT, L-NMMA and L-NAME, but not to a significant level ; cAMP was also increased in the homogenates from HUVECs treated with adenosine ( Figure 1B) . The increase in cAMP induced by adenosine was inhibited by the presence of the NOS inhibitors L-NMMA and L-NAME, suggesting that this enhancement in cAMP levels Subconfluent HUVECs were incubated in the presence of 500 nM thrombin, 10 µM adenosine and various concentrations of L-arginine. After washing the cells with Hepes-buffered saline, TF activity was determined. TF activity is expressed as a percentage of the control activity (thrombin alone). L-Arginine potentiated the inhibitory activity of adenosine on TF activity. Further, L-arginine itself was also able to inhibit thrombin-induced TF activity on HUVECs. Values are meanpS.E.M. for four independent experiments, each done in quadruplicate. *P 0.05.
depended, at least in part, on the intracellular production of cGMP.
Effect of adenosine-induced production of NO on TF activity in HUVECs
To investigate the role of adenosine-induced NO in the inhibitory effect of adenosine on TF activity, HUVECs pre-treated with thrombin and adenosine were incubated in the presence of various concentrations of the NO scavenger, carboxy-PTIO, or NOS inhibitors, L-NMMA and L-NAME. The results of the experiments showed that carboxy-PTIO (Figure 2A ) and NOS inhibitors ( Figure 2B ) block the inhibition of the cell surface TF activity by adenosine in a dose-dependent manner. The blockade of adenosine inhibitory activity was significant at concentrations over 6 µM and 1 mM for carboxy-PTIO and the NOS inhibitors respectively. The effect of the precursor of NO, L-arginine, on the inhibition of cell surface TF activity by adenosine was also evaluated. LArginine potentiated the adenosine-induced inhibition of TF activity on HUVECs (Figure 3) . Furthermore, Larginine itself was also able to inhibit thrombin-induced TF activity on HUVECs. These results implicate NO production in the mechanism of adenosine-induced inhibition of cell surface TF activity on endothelial cells. The concentrations used of carboxy-PTIO or those of the NOS inhibitors did not affect the viability of HUVECs. 
Effect of thrombin and adenosine on eNOS or iNOS mRNA expression in HUVECs
To evaluate the effect of thrombin and adenosine on the expression of eNOS or iNOS mRNA, HUVECs were incubated in the presence of thrombin, adenosine or 8-SPT, and the level of eNOS or iNOS gene transcription was evaluated by Northern blotting. Thrombin alone decreased and adenosine alone increased the steady-state transcript levels of eNOS gene (Figure 4) . Adenosine inhibited the down-regulation of eNOS mRNA levels induced by thrombin, and this effect was blocked by 8-SPT. Densitometric analysis showed that thrombin decreases and adenosine increases the steady state of eNOS mRNA levels significantly ( Figure 4B ). The eNOS mRNA levels in HUVECs treated with thrombin and adenosine were significantly higher compared with cells treated with thrombin alone. 8-SPT suppressed the inhibitory activity of adenosine on thrombin-induced inhibition of eNOS mRNA expression. On the other hand, the expression of iNOS mRNA was not significantly changed by the addition of adenosine to the HUVECs (results not shown). 
Effect of phosphodiesterase II inhibitor on TF activity
Activation of phosphodiesterase II is known to decrease intracellular generation of cAMP. Increased intracellular concentration of cGMP may up-regulate intracellular formation of cAMP by blocking the activity of phosphodiesterase II. To evaluate the effect of phosphodiesterase II inhibition on TF activity induced by thrombin, HUVECs were incubated in the presence of thrombin, a mixture of thrombin and adenosine, or a mixture of thrombin and adenosine plus increasing concentrations of EHNA, an inhibitor of phosphodiesterase II, and then TF activity was measured on the cells. It can be seen in Figure 5 (A) that adenosine significantly inhibited TF activity induced by thrombin on HUVECs ; the addition of EHNA provoked further inhibition of TF activity in a dose-dependent manner.
Effect of cAMP-dependent protein kinase inhibitor on NO-mediated inhibition of TF
The cAMP-dependent protein kinase has been reported to decrease the transcription of TF through components of the nuclear factor κB (NF-κB)\Rel family of transcription factors. To evaluate whether the cAMPdependent protein kinase is involved in the inhibitory activity of NO on thrombin-induced TF activity, HUVECs were cultured in the presence of thrombin, the NO donor FK409 and increasing concentrations of RpcAMPS, and then TF activity was measured at the surface of these cells. The results showed that FK409 significantly inhibited TF activity on HUVECs stimulated by thrombin ( Figure 5B ). This suppressive effect of NO on TF activity was significantly blocked by Rp-cAMPS at concentrations over 0.6 µM, suggesting the important role of cAMP-dependent protein kinase in the inhibition of TF expression by NO.
Effect of NO donor on adenosine secretion by HUVECs
It is known that both NO and adenosine increase and exert a cytoprotective activity at foci of tissue injury or hypoxia. As shown above, adenosine may stimulate the production of NO from endothelial cells in these pathological conditions. However, it is also conceivable that NO itself may stimulate the local production of adenosine. In the present study, this potential effect of NO on adenosine secretion was also evaluated in HUVECs. Significant increased levels of adenosine were observed in the supernatants of HUVECs treated with 50 µM NO donor (FK409) as compared with the controls (results not shown), suggesting that adenosine may also be secreted from endothelial cells by NO via an autocrine mechanism.
DISCUSSION
The vascular endothelium plays a critical role in the regulation of coagulation through the constitutive expression and release of anticoagulants, and the inducible expression of procoagulant substances [16] . TF is the clotting factor which mediates the procoagulant activity of the vascular endothelium. It is expressed on endothelial cells upon stimulation with inflammatory stimuli ; once expressed, plasma Factor VIIa binds to TF, and this TF-Factor VIIa complex activates the extrinsic pathway of blood coagulation [17] . Activation of this coagulation pathway, with subsequent thrombin generation, has been implicated in the mechanism of several pathological conditions, such as unstable angina, atherosclerosis, chronic inflammation and cancer [17] . The cellular effect of thrombin may be mediated by the protease-activated receptors-1, -3 or -4 present on the surface of several cells, including endothelial cells [18] . By acting on these receptors, thrombin itself may perpetuate coagulation activation by inducing the expression of TF on endothelial cells [7] . We have shown previously [7, 8] that adenosine may suppress this vicious cycle of thrombin formation by inhibiting thrombin-induced expression of TF on endothelial cells. Most of the physiological effects of adenosine take place by the action of adenosine at specific cell-surface receptors [19] . In a previous study [8] , we have shown that adenosine receptor antagonists, including 8-SPT, counteract the inhibitory activity of adenosine on TF and that adenosine receptor agonists block the TF expression in HUVECs ; these observations suggest that the effect of adenosine is mediated by its receptors.
Adenosine is normally produced during the basal metabolic activity of the cells. The extracellular concentration of adenosine increases dramatically (up to micromolar levels) during ischaemia and hypoxia, and it is believed to confer cytoprotection to the ischaemic tissue [8] . Adenosine also provides protective activity against ischaemia-reperfusion injury, and the beneficial effect of cardiac pre-conditioning has been attributed to the high concentration of adenosine in affected tissues [16] [17] [18] [19] [20] [21] . The mechanism of this protective effect of adenosine is not completely clear. Adenosine protects against injury by enhancing the activity of antioxidant enzymes (e.g., superoxide dismutase), which are known to play a key role in the elimination of reactive oxygen species generated during metabolic activity or ischaemiareperfusion injury [8, 22] . TF is also markedly expressed during hypoxia, ischaemic damage and ischaemiareperfusion injury [23] . Abnormal expression of TF has been involved in the pathogenesis of stable and unstable coronary syndromes, acute myocardial infarction, and acute thrombosis with vascular restenosis [24] [25] [26] [27] [28] . It has also been reported previously [29] that TF expressed on endothelial cells activates the coagulation system and induces tissue injury during the post-ischaemic cardiac reperfusion. Thus the observation that adenosine inhibits thrombin-induced TF activity may also constitute an important mechanism by which adenosine protects normal tissue against injury.
NO has been reported to mediate some of the biological actions of adenosine, such as the regulation of smooth muscle tone and protection against ischaemiareperfusion injury [30] [31] [32] . In the present study, we investigated whether adenosine inhibits TF expression on HUVECs by increasing the production of NO from these cells. Levels of the NO scavenger and NOS inhibitors decreased, and L-arginine potentiated the adenosine-mediated inhibition of TF activity on HUVECs in a dose-dependent manner, suggesting that the NO pathway is involved in the inhibitory activity of adenosine on TF expression. This inhibitory activity of adenosine depended on formation de novo of NO from endothelial cells, as shown by the increase in the concentrations of nitrite\nitrate and cGMP in HUVECs after treatment with adenosine, and by the suppressive effect on NO formation of the non-selective adenosine receptor antagonist, 8-SPT. In addition, we found that NO itself may stimulate the secretion of adenosine from HUVECs, suggesting the existence of an autocrine mechanism in the induction of NO by adenosine. Overall, these observations suggest that NO mediates, at least in part, the anticoagulant effect of adenosine on endothelial cells.
The major rate-limiting step in NO formation is the activity of NOS. There are two forms of NOS in endothelial cells, a constitutive eNOS and an iNOS [10] . The expression of iNOS may be induced by cytokines (TNF-α and IL-1) or lipopolysaccharide in endothelial cells ; however, in our present study, adenosine did not affect the expression of iNOS in HUVECs. With regards to eNOS, it was initially thought that eNOS transcript abundance was not affected by cytokines or other stimuli. However, previous studies [33] [34] [35] [36] [37] [38] have shown that the levels of eNOS mRNA may also be decreased by TNF-α, hypoxia, lipopolysaccharide or low-density lipoproteins, and increased by sex steroids or shear stress. The present study showed that thrombin may also downregulate the baseline expression of eNOS in HUVECs ; this inhibitory activity of thrombin on eNOS expression was suppressed by adenosine. The adenosine receptor antagonist 8-SPT blocked this protective activity of adenosine on eNOS gene transcription, suggesting that its effect is mediated by adenosine receptors. TNF-α and hypoxia were reported to decrease eNOS gene transcription by decreasing eNOS mRNA stability [38] ; thus, it is also conceivable that thrombin exerts its effect by decreasing, and adenosine by increasing, the stability of eNOS mRNA levels in endothelial cells.
The intracellular events involved in the inhibitory activity of adenosine on TF expression are not completely clear. Protein kinase C and protein tyrosine kinase are involved in the expression of TF by monocytes or endothelial cells in response to lipopolysaccharide, PMA and cytokines, such as TNF-α and IL-1 [39] [40] [41] . During the process of cellular activation, cytoplasmic NFκB-Rel complexes dissociate from the inhibitor protein IκBα, and the transcription factors translocate to the nucleus to initiate the expression of TF. Protease inhibitors that block the proteolysis of the inhibitor protein, IκBα, and agents that increase intracellular cAMP levels suppress the cellular expression of TF [42] [43] [44] . Activation of the NO-cGMP pathway is associated with increased intracellular cAMP formation [45] . The increased intracellular levels of cAMP observed in the present study depended on activation of the NO-cGMP pathway, because the NO inhibitors, L-NMMA and L-NAME, decreased cAMP levels in HUVECs. cGMP may increase Figure 6 Potential mechanism of TF inhibition by adenosine in HUVECs the intracellular level of cAMP by inhibiting phosphodiesterase II, and by this mechanism it may decrease TF activity [48] . In agreement with this, in the present study we found that the addition of EHNA, a phosphodiesterase II inhibitor, potentiates inhibition of TF activity on HUVECs in a dose-dependent manner. The mechanism of TF expression inhibition by intracellular cAMP is not clear, but some studies suggest that activation of cAMP-dependent protein kinases inhibits NFκB-mediated transcription of TF in human monocytes and endothelial cells [46] . To evaluate whether cAMPdependent protein kinase is also involved in the inhibitory activity of NO on thrombin-induced TF activity in endothelial cells, we stimulated HUVECs with thrombin in the presence of the NO donor, FK409, and the protein kinase inhibitor, Rp-cAMPS. The dose of FK409 used in this experiment was within the range at which it inhibits platelet aggregation (approx. 0.32 µM) and vasoconstriction (approx. 0.32 nM), as demonstrated in previous studies [47, 48] . The results showed that Rp-cAMPS blocks the suppressive effect of FK409 on TF activity in HUVECs in a dose-dependent manner, implicating the cAMP-dependent protein kinase in the NO-mediated inhibition of TF in HUVECs ( Figure 6) .
Overall, the results of this study suggest that adenosine inhibits thrombin-induced TF expression in endothelial cells by a NO-mediated mechanism, and that the increased intracellular formation of cAMP is implicated in this inhibitory activity of NO.
